CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. Escola Paulista de Medicina (EPM) (Institutional affiliation for the last research proposal) Birthplace: Brazil
Ricardo Sobhie Diaz was born on June 6th, 1962. Physician graduated from Escola Paulista de Medicina, Universidade Federal de São Paulo (EPM/UNIFESP) in 1986, with residency at this same Institution in Internal Medicine and Infectious Diseases between 1987 and 1989. Finished master degree in 1991 and doctorate degree in 1993 at EPM/UNIFESP. Worked his post doctoral in laboratory medicine studying the genetic diversity of HIV and its relationship to pathogenesis at the current Former Irwin Memorial Blood Centers in San Francisco, California, USA, by the University of California at Berkeley. He is Associate Professor and Associate Professor of infectious disease discipline at EPM / UNIFESP. He serves as Director of the Retrovirology Laboratory of this Institution, conducting research in virology, molecular biology, transitional (translational) research and clinical research with HIV and related viruses. Leads a group of researchers who conduct research in basic and clinical areas, including graduate students at various levels. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
1. Preliminary studies conducted by the team of Prof. Ricardo Sobhie Diaz, point out that combined strategies to (a) overcome residual HIV replication among people undergoing treatment, (b) overcome HIV latency and (c) eliminate HIV in so-called viral sanctuaries, have caused significant clinical impact and unexpected (NCT02961829) .1-19 Thus, initially pilot studies and proof of concept …
A modern and urgent challenge in fighting HIV infection is to achieve sustained HIV remission without the use of antiretrovirals. Our preliminary data indicate that the use of combined strategies to mitigate the HIV proviral reservoir size among individuals with suppressive antiretroviral treatment achieved unprecedented results in the reduction of HIV DNA present in these cells and in th…
AIDS, caused by human immunodeficiency virus (HIV), is a pandemic disease, affecting approximately 37 million people worldwide. Antiretroviral therapy (ART), typically comprising a combination of three drugs, cannot completely eradicate the virus from HIV positive individuals. The elimination of HIV from the body is hampered by the existence of long-lived viral reservoirs, mainly memory T…
This is an interventional proof of concept pilot study to explore the residual HIV replication. Thirty patients under effective HAART for over 2 years will be randomized after recruitment to six different groups and followed by 48 weeks. Group 1. Five patients will receive no further intervention in this group (control group) Group 2. Five patients will receive antiretroviral intensific…
The low genetic diversity of HIV in patients diagnosed with recent infection is a consequence of genetic bottleneck during transmission. However, some studies demonstrated by Sanger sequencing that this event happens less frequently in female patients, suggesting that women have greater susceptibility to be primarily infected by multiple HIV variants. Hypothetically, HIV-infected women ma…
(Only some records are available in English at this moment)
Despite the ability of the antiretroviral therapy at controlling the HIV-1 replication, there are obstacles that prevent the eradication of the infection. The obstacles that prevent the sterilizing cure of HIV-1 infection are the establishment of viral reservoirs that give rise to residual replication and the viral latency. It is known that viral latency is maintained at least in part by …
his project will contribute to the thematic project Multiple interventions to eliminate HIV reservoirs among antiretroviral treated individuals to obtain sustained HIV remission without antiretrovirals support in the areas of bioinformatics and statistics, applying the techniques of these two disciplines to the biological and clinical analyses that derive from the overall project. The fi…
Highly Active Antiretroviral Therapy (HAART) has been shown great results. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are widely used as first-line therapy. In Brazil, the therapy comprises the first-generation NNRTIs, nevirapine, and efavirenz, and also the second-generation NNRTI, etravirine. These drugs change the HIV-1 reverse transcriptase conformation, an alteration th…
HIV-1 is the main cause of Acquired Immunodeficiency Syndrome (AIDS), characterized by low concentrations of CD4 + T lymphocytes and a high viral replication, leading to the appearance of opportunistic diseases. Most patients are treated with antiretroviral drugs, which act mainly on mechanisms of viral infection in order to reduce cell activation and thereby prevent an increase in viral …
The tremendous genetic variability of HIV has a direct impact on the development of molecular diagnostic tests and is a serious hurdle that confronts research in the development of a vaccine to counter the virus. It is therefore important to monitor the distribution and dynamics of HIV subtypes to avoid vaccination failure and a pitfall for molecular diagnostics The main objective of the …
(Only some records are available in English at this moment)
| 2 / 2 | Ongoing research grants |
| 17 / 7 | Completed research grants |
| 2 / 2 | Ongoing scholarships in Brazil |
| 31 / 4 | Completed scholarships in Brazil |
| 1 / 0 | Completed scholarships abroad |
| 53 / 15 | All research grants and scholarships |
| Associated processes | |